## SKIN REACTION MANAGEMENT PATHWAY



- History of skin allergies
- Skin reaction observed following dressing removal
- On chemotherapy or have history of chemotherapy
- 2. Ensure Cavilon® no sting barrier skin protectant has been used
- **3.** Monitor site closely
- 4. Accurately document change in the skin integrity

2.

3.

- 1. Discontinue chlorhexidine 2% with alcohol 70% skin antisepsis
- 2. Replace with alcohol 70% only to clean the insertion site
- 3. Continue to use SorbaVeiw 'Adhesive free zone' dressing -when removing dressing use an alcohol swab to deactivate the adhesive and reduce skin trauma
- 4. Consider an oral non-sedating antihistamine for pruritus or apply an ice pack to the area over the dressing area to cool the skin

**Still Reacting?** 

**Recommended dressing** 

Skin Reacted?

- 1. Discontinue alcohol 70% skin antisepsis.
  - Consider povidine-iodine. PVP-I \*(alcohol free)
     \* BEFORE using PVP-I ensure a skin patch test is carried out for sensitivity (Read patch 48 hours following application)
     Do not use if positive skin reaction to PVP-I.
- a. Use the alternative 0.9% sodium chloride -10mL sterile single use amp
- b. Discontinue dressing and document brand name
- c. If skin reaction occurs apply 1% hydrocortisone cream(one application only) to area and dress with sterile gauze secured with silicone tape
- d. Assess site at 24 hours. If reaction has settled introduce occlusive dressing
- e. Introduce dressing as listed in numerical order of effectiveness refer Box 4
- f. Daily assessment and documentation of skin integrity
- 4. 1. Sorbaveiw 2000 SV-40XT-6 oracle code: 294109
  2. 3M Tegaderm IV Advanced 1685 oracle code: 255998
  3. Sterile gauze secured with silicone tape (use following application of hydrocortisone cream refer box 3 point c as above) 3M Kind silicone tape 2.5cm x 5m oracle code: 161800
  Maintain the same skin preparation regime as indicated in box 3

Source: Kutzscher, L. (2012). Management of Irritant Contact Dermatitis and Peripherally Inserted Central Catheters. *Clinical Journal of Oncology Nursing*. Volume 16, Number 2.